Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04074759




Registration number
NCT04074759
Ethics application status
Date submitted
13/08/2019
Date registered
30/08/2019
Date last updated
28/02/2024

Titles & IDs
Public title
FPT155 in Patients With Advanced Solid Tumors
Scientific title
A Phase 1 Safety and Tolerability Study of FPT155 in Patients With Advanced Solid Tumors
Secondary ID [1] 0 0
FPT155-001
Universal Trial Number (UTN)
Trial acronym
FPT155-001
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - FPT155
Other interventions - pembrolizumab

Experimental: FPT155 monotherapy - The study consists of dose escalation and cohort expansions

Experimental: FPT155 in combination with pembrolizumab - The study consists of dose escalation and cohort expansions


Other interventions: FPT155
A soluble CD80 fusion protein

Other interventions: pembrolizumab
An anti-PD1 antibody
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Monotherapy: Maximum tolerated dose (MTD) of FPT155
Timepoint [1] 0 0
Approximately 16 months
Primary outcome [2] 0 0
Monotherapy: Incidence of treatment emergent adverse events
Timepoint [2] 0 0
Through study completion, approximately 30 months
Primary outcome [3] 0 0
FPT155 + pembrolizumab: Maximum tolerated dose (MTD) of FPT155
Timepoint [3] 0 0
Approximately 12 months
Primary outcome [4] 0 0
FPT155 + pembrolizumab: Incidence of treatment emergent adverse events
Timepoint [4] 0 0
Through study completion, approximately 30 months
Secondary outcome [1] 0 0
Pharmacokinetic profile FPT155
Timepoint [1] 0 0
Through study completion, approximately 30 months
Secondary outcome [2] 0 0
Incidence of treatment emergent anti-FPT155 antibody response
Timepoint [2] 0 0
Through study completion, approximately 30 months
Secondary outcome [3] 0 0
Pharmacokinetic profile FPT155
Timepoint [3] 0 0
Through study completion, approximately 30 months
Secondary outcome [4] 0 0
Pharmacokinetic profile FPT155
Timepoint [4] 0 0
Through study completion, approximately 30 months
Secondary outcome [5] 0 0
Pharmacokinetic profile FPT155
Timepoint [5] 0 0
Through study completion, approximately 30 months
Secondary outcome [6] 0 0
Pharmacokinetic profile FPT155
Timepoint [6] 0 0
Through study completion, approximately 30 months
Secondary outcome [7] 0 0
Pharmacokinetic profile FPT155
Timepoint [7] 0 0
Through study completion, approximately 30 months
Secondary outcome [8] 0 0
Objective response rate
Timepoint [8] 0 0
Through study treatment, approximately a median of 6 months
Secondary outcome [9] 0 0
Cohort Expansions only: Progression-free survival
Timepoint [9] 0 0
Approximately a median of 6 months
Secondary outcome [10] 0 0
Cohort Expansions only: Duration of response
Timepoint [10] 0 0
Approximately a median of 9 months

Eligibility
Key inclusion criteria
- Histologically confirmed solid tumors (except primary central nervous system tumors).
For patients enrolled for treatment with FPT155+pembrolizumab: histologically
confirmed non-small cell lung cancer not eligible for curative therapy.

- Disease that is unresectable, locally advanced, or metastatic and has progressed
following all standard treatments or is not appropriate for standard treatments

- All patients must have at least one measurable lesion at baseline according to RECIST
v1.1

- Availability of archival tumor tissue and consent to provide archival tumor for
retrospective biomarker analysis, or consent to undergo a fresh tumor biopsy during
screening

- For patients participating in cohort expansions: consent to undergo a mandatory fresh
tumor biopsy during screening and on treatment

- ECOG performance status of 0 or 1

- Prior radiotherapy must be completed at least 2 weeks before first dose of study
treatment administration. No radiopharmaceuticals (eg, strontium, samarium) within 8
weeks before first dose of study treatment administration.

- Prior surgery that requires general anesthesia must be completed at least 14 days
before first dose of study treatment

- Adequate bone marrow, liver and kidney function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Uncontrolled or significant cardiac disease

- Any uncontrolled medical condition or psychiatric disorder including infection,
autoimmune disease, bleeding disorder or symptomatic involvement of the central
nervous system

- Treatment with any anti-cancer therapy or participation in another investigational
drug or biologics trial within 28 days or = 5 half-lives (whichever is shorter)

- Patients who discontinue prior immune-modulating therapies (including regimens
containing an immune agonist or a PD-L1/PD-1 antagonist) due to toxicity or have
received treatment within 5 half lives or 90 days

- Pregnancy or breastfeeding

- For patients participating in cohort expansion: Prior treatment with a CTLA-4
antagonist, including ipilimumab and tremelimumab

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/10/2021
Sample size
Target
Accrual to date
Final
80
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [3] 0 0
Scientia Clinical Research - Randwick
Recruitment hospital [4] 0 0
ICON - Auchenflower
Recruitment hospital [5] 0 0
Olivia Newton-John Cancer Center - Heidelberg
Recruitment hospital [6] 0 0
Cabrini Hospital - Malvern
Recruitment hospital [7] 0 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
2031 - Randwick
Recruitment postcode(s) [4] 0 0
4066 - Auchenflower
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
3144 - Malvern
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
Korea, Republic of
State/province [1] 0 0
Gyeonggi-do
Country [2] 0 0
Korea, Republic of
State/province [2] 0 0
Seoul

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Five Prime Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, and activity of FPT155 as monotherapy in
patients with advanced solid tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04074759
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04074759